Reuters logo
Lundbeck to acquire Chelsea Therapeutics for up to $658 mln
May 8, 2014 / 12:10 PM / 4 years ago

Lundbeck to acquire Chelsea Therapeutics for up to $658 mln

COPENHAGEN, May 8 (Reuters) - Danish pharmaceutical company H. Lundbeck said it had entered into a definitive agreement with Chelsea Therapeutics under which it will acquire the U.S. company.

Chelsea stockholders are entitled to $6.44 per share in cash and contingent value rights (CVRs) that may pay up to 1.50 dollar, corresponding to $658 million on a fully diluted basis, Lundbeck said.

The total potential consideration represents a premium of 59 percent over the closing price of Chelsea shares on May 7, Lundbeck added. (Reporting by Teis Jensen; Editing by Pravin Char)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below